

the **pharma**letter

Bayer buys rights to “female Viagra” for C\$330 million; Johnson & Johnson proceeds with \$2.42 billion bid for Crucell

Article | 6 October 2010

 [Print This](#)  [Share This](#)

Bayer HealthCare Pharmaceuticals, a unit of Germany’s Bayer (BAY: DE) has entered into an accord with Quebec, Canada-based EndoCeutics for Phase III development and worldwide marketing of dehydroepiandrosterone (DHEA), a new treatment for vaginal atrophy and female sexual dysfunction for which a provisional trade name Vaginorm has been proposed.

Bayer’s partnership with EndoCeutics may mean up to about C\$330 million (\$322. Enjoying this article? To continue reading you need to [login](#) or [subscribe](#).

<http://www.thepharmaletter.com/file/98861/bayer-buys-rights-to-female-viagra-for-c330-million-johnson-johnson-proceeds-with-242-billion-bid-for-crucell.html>